Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -27.40M | -217.76M | -8.89M | -9.38M | -16.82M |
| Total Depreciation and Amortization | 882.00K | 7.92M | 7.92M | 7.91M | 7.91M |
| Total Amortization of Deferred Charges | 5.33M | 5.10M | 4.88M | 4.67M | 4.47M |
| Total Other Non-Cash Items | 6.37M | 210.77M | -6.10M | -2.69M | -3.06M |
| Change in Net Operating Assets | -5.37M | -9.05M | 9.80M | -12.06M | 486.00K |
| Cash from Operations | -20.19M | -3.02M | 7.61M | -11.56M | -7.02M |
| Capital Expenditure | -- | -44.00K | -220.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -44.00K | -220.00K | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -93.00K | 93.00K | -157.00K | 155.00K | 97.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.28M | -2.97M | 7.23M | -11.40M | -6.92M |
